Congresswoman Sydney Kamlager-Dove, who represents California’s 37th district in the U.S. Congress, recently posted a series of tweets addressing topics ranging from pharmaceutical drug risks to concerns about government actions under former President Trump.
On December 4, 2025, Kamlager-Dove commented on the Alzheimer’s drug Leqembi, listing its administration method and potential side effects: “The Alzheimer’s drug Leqembi:
– Is administered through an infusion (for example, through the hand)
– Can cause swelling, bleeding, or fluid leakage in the brain, requiring regular MRIs
– Can cause tiredness
Curious. https://t.co/QrZV23fdG9“.
A day later, on December 5, 2025, she posted about her concerns regarding government conduct during Donald Trump’s presidency: “Under Trump, the United States of America is now in the business of disappearing people—and the Trump regime doesn’t seem to care who. https://t.co/KuexJ8XWVg”.
Later that same day, Kamlager-Dove tweeted a brief message referencing online chat activity: “This chat’s kinda dead. Anything going on?” https://t.co/jqPsHMwyRQ https://t.co/jitKpkrVjR.
Sydney Kamlager-Dove has served as a member of Congress since 2023 after replacing Karen Bass. She previously held positions in both the California State Assembly and Senate between 2018 and 2023. Born in Chicago in 1972 and currently residing in Los Angeles, Kamlager-Dove graduated from the University of Southern California with a Bachelor of Arts degree in 1994.
